A spokesperson for the sunscreen advocacy group is hopeful that a National Academies of Sciences study on the way will convince Maui County not to ban non-chemical sunscreens as planned in October. At the same time, “We’re very concerned that there are members of the Maui County Council that would prefer to just ban everything rather than wait for the science,” she said.
Legislation to ban additional UV filters in sunscreen products sold in Hawaii has been put on ice, but Maui County is still on track to prohibit sales of all non-mineral sunscreens, effective on 1 October 2022.
That has industry advocates pivoting from state-level advocacy to focus on Maui County, which comprises the islands of Maui, Molokai,...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
